Reckitt Benckiser Group (RB) Price Target Lowered to GBX 5,800 at Credit Suisse Group

Share on StockTwits

Reckitt Benckiser Group (LON:RB) had its target price reduced by investment analysts at Credit Suisse Group from GBX 6,000 ($78.40) to GBX 5,800 ($75.79) in a report released on Tuesday. The firm currently has an “underperform” rating on the stock. Credit Suisse Group’s price objective would indicate a potential downside of 2.60% from the stock’s previous close.

Several other research firms also recently weighed in on RB. Royal Bank of Canada set a GBX 5,100 ($66.64) target price on shares of Reckitt Benckiser Group and gave the stock a “sell” rating in a research report on Wednesday, January 16th. Liberum Capital reissued a “buy” rating and set a GBX 7,600 ($99.31) target price on shares of Reckitt Benckiser Group in a research report on Tuesday, October 30th. UBS Group reaffirmed a “neutral” rating and issued a GBX 6,400 ($83.63) price objective (up from GBX 6,300 ($82.32)) on shares of Reckitt Benckiser Group in a report on Monday, January 14th. Jefferies Financial Group set a GBX 5,000 ($65.33) price objective on shares of Reckitt Benckiser Group and gave the company a “sell” rating in a report on Wednesday, February 6th. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Reckitt Benckiser Group in a report on Wednesday, January 30th. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the company’s stock. Reckitt Benckiser Group has an average rating of “Hold” and a consensus price target of GBX 6,871.67 ($89.79).

LON:RB opened at GBX 5,955 ($77.81) on Tuesday. Reckitt Benckiser Group has a twelve month low of GBX 5,562 ($72.68) and a twelve month high of GBX 8,110.43 ($105.98).

About Reckitt Benckiser Group

Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.

Further Reading: Trading Options- What is a Strangle?

Analyst Recommendations for Reckitt Benckiser Group (LON:RB)

Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

InZinc Mining  Shares Up 28.6%
InZinc Mining Shares Up 28.6%
Cellular Biomedicine Group  Releases  Earnings Results
Cellular Biomedicine Group Releases Earnings Results
Cincinnati Financial Co.  Director Dirk J. Debbink Acquires 351 Shares
Cincinnati Financial Co. Director Dirk J. Debbink Acquires 351 Shares
Insider Selling: Paratek Pharmaceuticals Inc  Director Sells 3,375 Shares of Stock
Insider Selling: Paratek Pharmaceuticals Inc Director Sells 3,375 Shares of Stock
PS Business Parks  Posts  Earnings Results, Misses Expectations By $0.48 EPS
PS Business Parks Posts Earnings Results, Misses Expectations By $0.48 EPS
Yamana Gold Inc.  Senior Officer Richard Campbell Sells 12,776 Shares of Stock
Yamana Gold Inc. Senior Officer Richard Campbell Sells 12,776 Shares of Stock


Leave a Reply

© 2006-2019 Ticker Report